MK-6552
/ Merck (MSD)
- LARVOL DELTA
Home
Next
Prev
1 to 12
Of
12
Go to page
1
December 04, 2024
A Study of MK-6552 and the Effect of Food in Healthy Participants (MK-6552-006)
(clinicaltrials.gov)
- P1 | N=24 | Terminated | Sponsor: Merck Sharp & Dohme LLC | Active, not recruiting ➔ Terminated; Business Reasons
Trial termination
November 18, 2024
Study of MK-6552 in Participants With Narcolepsy Type 1 (MK-6552-004)
(clinicaltrials.gov)
- P1 | N=9 | Terminated | Sponsor: Merck Sharp & Dohme LLC | N=24 ➔ 9 | Trial completion date: Jun 2025 ➔ Oct 2024 | Recruiting ➔ Terminated | Trial primary completion date: Jun 2025 ➔ Oct 2024; Terminated for business reasons
Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Narcolepsy • Sleep Disorder
October 28, 2024
A Study of Diltiazem With a Single Dose of MK-6552 in Healthy Adult Participants (MK-6552-007)
(clinicaltrials.gov)
- P1 | N=14 | Completed | Sponsor: Merck Sharp & Dohme LLC
New P1 trial
October 30, 2024
A Clinical Study of MK-6552 and Modafinil in Healthy Men (MK-6552-005)
(clinicaltrials.gov)
- P1 | N=12 | Completed | Sponsor: Merck Sharp & Dohme LLC
New P1 trial • Narcolepsy • Sleep Disorder
October 16, 2024
A Study of MK-6552 and the Effect of Food in Healthy Participants (MK-6552-006)
(clinicaltrials.gov)
- P1 | N=24 | Active, not recruiting | Sponsor: Merck Sharp & Dohme LLC | Recruiting ➔ Active, not recruiting
Enrollment closed
October 01, 2024
A Study of MK-6552 in Sleep Deprived Healthy Participants (MK-6552-003)
(clinicaltrials.gov)
- P1 | N=18 | Completed | Sponsor: Merck Sharp & Dohme LLC
New P1 trial • Narcolepsy • Sleep Disorder
September 21, 2024
Study of MK-6552 in Participants With Narcolepsy Type 1 (MK-6552-004)
(clinicaltrials.gov)
- P1 | N=24 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | N=12 ➔ 24
Enrollment change • Narcolepsy • Sleep Disorder
September 20, 2024
A Study of MK-6552 and the Effect of Food in Healthy Participants (MK-6552-006)
(clinicaltrials.gov)
- P1 | N=24 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | Not yet recruiting ➔ Recruiting
Enrollment open
August 22, 2024
A Study of MK-6552 and the Effect of Food in Healthy Participants (MK-6552-006)
(clinicaltrials.gov)
- P1 | N=24 | Not yet recruiting | Sponsor: Merck Sharp & Dohme LLC
New P1 trial
August 20, 2024
Study of MK-6552 in Participants With Narcolepsy Type 1 (MK-6552-004)
(clinicaltrials.gov)
- P1 | N=12 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | Trial completion date: Dec 2024 ➔ Jun 2025 | Trial primary completion date: Dec 2024 ➔ Jun 2025
Trial completion date • Trial primary completion date • Narcolepsy • Sleep Disorder
February 06, 2024
Study of MK-6552 in Participants With Narcolepsy Type 1 (MK-6552-004)
(clinicaltrials.gov)
- P1 | N=12 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | Not yet recruiting ➔ Recruiting
Enrollment open • Narcolepsy • Sleep Disorder
December 21, 2023
Study of MK-6552 in Participants With Narcolepsy Type 1 (MK-6552-004)
(clinicaltrials.gov)
- P1 | N=12 | Not yet recruiting | Sponsor: Merck Sharp & Dohme LLC
New P1 trial • Narcolepsy • Sleep Disorder
1 to 12
Of
12
Go to page
1